Piroxicam inhibits herpes simplex virus type 1 infection in vitro

• Verfasst von: Astani, Akram [VerfasserIn]
• Verfasst von: Albrecht, U. [VerfasserIn]
• Verfasst von: Schnitzler, Paul [VerfasserIn]
• Titel: Piroxicam inhibits herpes simplex virus type 1 infection in vitro
• Verf.angabe: A. Astani, U. Albrecht, P. Schnitzler
• E-Jahr: 2015
• Jahr: 1. Mai 2015
• Umfang: 6 S.
• Fussnoten: Gesehen am 28.07.2020
• Titel Quelle: Enthalten in: Die Pharmazie <Eschborn>
• Ort Quelle: Eschborn : Avoxa, Mediengruppe Deutscher Apotheker, 1995
• Jahr Quelle: 2015
• Band/Heft Quelle: 70(2015), 5, Seite 331-336
• DOI: doi:10.1691/ph.2015.4791
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1725650266

Abstract

Piroxicam is a potent, nonsteroidal, anti-inflammatory agent (NSAID) which also exhibits antipyretic activity. The antiviral effect of piroxicam against herpes simplex virus type 1 (HSV-1) was examined in vitro on RC-37 monkey kidney cells using a plaque reduction assay. Piroxicam - was dissolved in ethanol or dimethylsulfoxide (DMSO) and the 50% inhibitory concentration (IC50) was determined at 4 μg/ml and 75 μg/ml, respectively. The IC50 for the standard antiherpetic drug acyclovir was determined at 1.6 μM. At non-cytotoxic concentrations - of these piroxicam solutions, plaque formation was significantly reduced by 62.4% for ethanolic piroxicam and 72.8% for piroxicam in DMSO. The mode of antiviral action of these drugs was assessed by time-on-addition assays. No antiviral effect was observed when cells were incubated with piroxicam - prior to infection with HSV-1 or when HSV-1 infected cells were treated with dissolved piroxicam. Herpesvirus infection was, however, significantly inhibited when HSV-1 was incubated with piroxicam prior to the infection of cells. These results indicate that piroxicam affected the virus before - adsorption, but not after penetration into the host cell, suggesting that piroxicam exerts a direct antiviral effect on HSV-1. Free herpesvirus was sensitive to piroxicam in a concentration-dependent manner and the inhibition of HSV-1 appears to occur before entering the cell but not after - penetration of the virus into the cell. Considering the lipophilic nature of piroxicam, which enables it to penetrate the skin, it might be suitable for topical treatment of herpetic infections.